OncoPharm podcast

Paradigm and Daraxonrasib in NSCLC

03/09/2026
0:00
14:31
Reculer de 15 secondes
Avancer de 15 secondes
PARADIGM is finally published, so we have more details from this study presented at ASH about HMA/Ven vs. Intensive Chemo if fit patients with AML. Daraxonrasib looks like a promising drug for RAS-mutant NSCLC, too. Download the Oncology Learning Companion: https://www.kelleycpharmd.com/learning-oncology-companion-oncopharm

D'autres épisodes de "OncoPharm"